When you choose Makena® (hydroxyprogesterone caproate injection) for your patients, you get more than the medicine. You get one centralized resource that’s designed specifically to assist your patients throughout their Makena experience.
At Makena Care Connection®, we offer personalized support that helps make filling prescriptions easier, addresses your patients’ financial concerns, and encourages adherence to therapy. Your patients won’t just get Makena to help reduce the risk of recurrent preterm birth, but also the support when they need it.
Together we can work toward one goal—helping your patients achieve a full-term pregnancy. Our dedicated staff at Makena Care Connection is ready to connect your patients to support and work with you to help ensure a timely start to therapy.
Have Questions? Connect with us.
1-800-847-3418 • 8 AM–8 PM ET • info@makenacareconnection.com
Connecting You, Your Staff, & Your Patients to Personalized Support
Each woman is unique and so are her insurance benefits. Because timely access is so important to your practice, we’ll aid in processing prescriptions, verifying insurance coverage, and obtaining prior authorizations (when applicable) to help your patients get their Makena prescription on time.
Completing the Makena Prescription Form:
eMakena makes things easier. Prescribe online. Connect patients to support programs. All in one place.
You can prescribe Makena through our online portal. This added resource lets you submit the prescription and prior authorization form (when applicable), track progress, and connect patients to support programs. To get started, visit iAssist.com.
“The Makena Care Connection gives me peace of mind about access to Makena. My patients are navigated through coverage determination based on their benefits and connected to financial assistance when needed.”
–David Gandell, MD, FACOG
We believe patients should be able to focus more on their pregnancy than the cost of their medication. To support that, AMAG Pharmaceuticals is committed to ensuring affordable access to Makena. We proactively screen and offer eligible patients financial assistance with no income caps.
*Each patient’s eligibility is evaluated on an individual basis. To be eligible, patients must meet the FDA-approved indication (pregnant with a single baby with a history of singleton spontaneous preterm birth <37 weeks)1. In compliance with federal regulations, patients insured by a government-funded program (eg, Medicaid, TRICARE, etc.) are not eligible.
If your patient feels her out-of-pocket cost is too high, she should call Makena Care Connection to see if she is eligible for financial assistance*
“I was so happy that I was approved for financial assistance. I feel very thankful that my family and I had this opportunity with the Makena Care Connection.”
– Nalleli, Makena mom
We can help coordinate Makena injections through a home healthcare organization. Once approved by insurance, moms prescribed Makena can choose to receive their injections by a healthcare professional in the comfort of their home or another location that’s convenient for them.
Benefits may include:
We understand that moms receiving Makena injections may need some encouragement and support to stick to their weekly injection schedule, and we want to help. This free service offers educational and adherence support to encourage women to make Makena part of their pregnancy and take an active role in their health.
A level of personalized support you and your patients can expect:
“Knowing she was just a phone call away gave me peace of mind. I appreciated feeling like I had someone supporting me every step of the way.”
–Shanise, Makena mom
We Speak Your Patient’s Language
We’re ready to help your patients with translation services in more than 240 languages. So communicating with moms on Makena isn’t a barrier.
Cigna Tel-Drug Home Delivery Services
1-800-351-3606
CVS Caremark Specialty Pharmacy
1-800-237-2767
Humana Pharmacy, Inc.
1-855-264-0104
Option Care
1-855-275-9647
Prime Therapeutics Specialty Pharmacy™
1-877-627-6337
Walgreens Specialty Pharmacy
1-888-347-3416
Prime Therapeutics Specialty Pharmacy LLC (Prime Specialty Pharmacy) is a wholly owned subsidiary of Prime Therapeutics LLC.
When in doubt, ask
If you or your patient is ever in doubt regarding the status of the Makena prescription, please contact Makena Care Connection at 1-800-847-3418 or email info@makenacareconnection.com.
If you know which pharmacy is dispensing your patient's prescription, you can call it directly.
Want to purchase Makena for your office? Learn how
Makena Prescription Form
To initiate the Makena prescription process via Makena Care Connection.
DownloadMakena Authorization for Release of Personal Health Information Form (HIPAA form)
If the patient does not sign Step 2 (Patient Authorization) of the Makena Prescription Form, this form may be completed and faxed to Makena Care Connection at a later date. The HIPAA release form allows Makena Care Connection to communicate with the healthcare provider, insurer, and specialty pharmacy on the patient's behalf. Note: this form does not need to be completed if the patient has already signed Step 2 of the Makena Prescription Form.
English SpanishMakena (hydroxyprogesterone caproate injection) is a progestin indicated to reduce the risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth. The effectiveness of Makena is based on improvement in the proportion of women who delivered <37 weeks of gestation. There are no controlled trials demonstrating a direct clinical benefit, such as improvement in neonatal mortality and morbidity.
Limitation of use: While there are many risk factors for preterm birth, safety and efficacy of Makena has been demonstrated only in women with a prior spontaneous singleton preterm birth. It is not intended for use in women with multiple gestations or other risk factors for preterm birth.
Please see full Prescribing Information for Makena.
Reference: 1. Makena® (hydroxyprogesterone caproate injection) prescribing information, AMAG Pharmaceuticals, 2016.